Search

Your search keyword '"Ayuk, Francis"' showing total 33 results
Start Over Author "Ayuk, Francis" Search Limiters Peer Reviewed Publication Year Range This year
33 results on '"Ayuk, Francis"'

1. Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)

Author

Finke, Jürgen, Schmoor, Claudia, Ayuk, Francis, Hasenkamp, Justin, Verbeek, Mareike, Wagner, Eva-Maria, Biersack, Harald, Schäfer-Eckart, Kerstin, Wolf, Dominik, Stuhler, Gernot, Reibke, Roland, Schmid, Christoph, Kaufmann, Martin, Eder, Matthias, Bertz, Hartmut, and Grishina, Olga

Published
2024
Full Text
View/download PDF

2. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

Author

Lübke, Johannes, Christen, Deborah, Schwaab, Juliana, Kaiser, Anne, Naumann, Nicole, Shoumariyeh, Khalid, Jentzsch, Madlen, Sockel, Katja, Schaffrath, Judith, Ayuk, Francis A., Stelljes, Matthias, Hilgendorf, Inken, Sala, Elisa, Kaivers, Jennifer, Schönland, Stefan, Wittke, Christoph, Hertenstein, Bernd, Radsak, Markus, Kaiser, Ulrich, Brückl, Valeska, Kröger, Nicolaus, Brümmendorf, Tim H., Hofmann, Wolf-Karsten, Klein, Stefan, Jost, Edgar, Reiter, Andreas, and Panse, Jens

Published
2024
Full Text
View/download PDF

7. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

Author

DeFilipp, Zachariah, Kim, Haesook T., Spyrou, Nikolaos, Katsivelos, Nikolaos, Kowalyk, Steven, Eng, Gilbert, Kasikis, Stelios, Beheshti, Rahnuma, Baez, Janna, Akahoshi, Yu, Ayuk, Francis, Choe, Hannah, Etra, Aaron, Grupp, Stephan A., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Qayed, Muna, Reshef, Ran, Vasova, Ingrid, Zeiser, Robert, Young, Rachel, Holler, Ernst, Ferrara, James L. M., Nakamura, Ryotaro, Levine, John E., and Chen, Yi-Bin

Published
2024
Full Text
View/download PDF

8. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

Author

Etra, Aaron, El Jurdi, Najla, Katsivelos, Nikolaos, Kwon, Deukwoo, Gergoudis, Stephanie, Morales, George, Spyrou, Nikolaos, Kowalyk, Steven, Aguayo-Hiraldo, Paibel, Akahoshi, Yu, Ayuk, Francis, Baez, Janna, Betts, Brian C., Chanswangphuwana, Chantiya, Chen, Yi-Bin, Choe, Hannah, DeFilipp, Zachariah, Gleich, Sigrun, Hexner, Elizabeth, Hogan, William J., Holler, Ernst, Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr, MacMillan, Margaret, Pawarode, Attaphol, Quagliarella, Francesco, Qayed, Muna, Reshef, Ran, Schechter, Tal, Vasova, Ingrid, Weisdorf, Daniel, Wölfl, Matthias, Young, Rachel, Nakamura, Ryotaro, Ferrara, James L. M., Levine, John E., and Holtan, Shernan

Published
2024
Full Text
View/download PDF

9. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

Author

Akahoshi, Yu, Spyrou, Nikolaos, Hoepting, Matthias, Aguayo-Hiraldo, Paibel, Ayuk, Francis, Chanswangphuwana, Chantiya, Choe, Hannah K., Eder, Matthias, Etra, Aaron M., Grupp, Stephan A., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr M., Merli, Pietro, Qayed, Muna, Reshef, Ran, Schechter, Tal, Ullrich, Evelyn, Vasova, Ingrid, Wölfl, Matthias, Zeiser, Robert, Baez, Janna, Beheshti, Rahnuma, Eng, Gilbert, Gleich, Sigrun, Kasikis, Stelios, Katsivelos, Nikolaos, Kowalyk, Steven, Morales, George, Young, Rachel, DeFilipp, Zachariah, Ferrara, James L. M., Levine, John E., and Nakamura, Ryotaro

Published
2024
Full Text
View/download PDF

10. A Day 14 Endpoint for Acute GVHD Clinical Trials

Author

Spyrou, Nikolaos, Akahoshi, Yu, Kowalyk, Steven, Morales, George, Beheshti, Rahnuma, Aguayo-Hiraldo, Paibel, Al Malki, Monzr M., Ayuk, Francis, Bader, Peter, Baez, Janna, Capellini, Alexandra, Choe, Hannah, DeFilipp, Zachariah, Eder, Matthias, Eng, Gilbert, Etra, Aaron, Gleich, Sigrun, Grupp, Stephan A., Hexner, Elizabeth, Hoepting, Matthias, Hogan, William J., Kasikis, Stelios, Katsivelos, Nikolaos, Khan, Alina, Kitko, Carrie L., Kraus, Sabrina, Kwon, Deukwoo, Merli, Pietro, Portelli, Joseph, Qayed, Muna, Reshef, Ran, Schechter, Tal, Vasova, Ingrid, Wölfl, Matthias, Wudhikarn, Kitsada, Young, Rachel, Holler, Ernst, Chen, Yi-Bin, Nakamura, Ryotaro, Levine, John E., and Ferrara, James L.M.

Published
2024
Full Text
View/download PDF

11. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Author

Akahoshi, Yu, Spyrou, Nikolaos, Weber, Daniela, Aguayo-Hiraldo, Paibel, Ayuk, Francis, Chanswangphuwana, Chantiya, Choe, Hannah K., Eder, Matthias, Etra, Aaron M., Grupp, Stephan A., Hexner, Elizabeth O., Hogan, William J., Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr M., Merli, Pietro, Qayed, Muna, Reshef, Ran, Schechter, Tal, Ullrich, Evelyn, Vasova, Ingrid, Wölfl, Matthias, Zeiser, Robert, Baez, Janna, Beheshti, Rahnuma, Eng, Gilbert, Gleich, Sigrun, Katsivelos, Nikolaos, Kowalyk, Steven, Morales, George, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Levine, John E., and Ferrara, James L. M.

Published
2024
Full Text
View/download PDF

12. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

Author

Qayed, Muna, Kapoor, Urvi, Gillespie, Scott, Westbrook, Adrianna, Aguayo-Hiraldo, Paibel, Ayuk, Francis A., Aziz, Mina, Baez, Janna, Choe, Hannah, DeFilipp, Zachariah, Etra, Aaron, Grupp, Stephan A., Hexner, Elizabeth, Holler, Ernst, Hogan, William J., Kowalyk, Steven, Merli, Pietro, Morales, George, Nakamura, Ryotaro, Pulsipher, Michael A., Schechter, Tal, Shah, Jay, Spyrou, Nikolaos, Srinagesh, Hrishikesh K., Wölfl, Matthias, Yanik, Gregory, Young, Rachel, Kitko, Carrie L., Ferrara, James L.M., and Levine, John E.

Published
2024
Full Text
View/download PDF

14. Correction: Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)

Author

Finke, Jürgen, primary, Schmoor, Claudia, additional, Ayuk, Francis, additional, Hasenkamp, Justin, additional, Verbeek, Mareike, additional, Wagner, Eva-Maria, additional, Biersack, Harald, additional, Schäfer-Eckart, Kerstin, additional, Wolf, Dominik, additional, Stuhler, Gernot, additional, Reibke, Roland, additional, Schmid, Christoph, additional, Kaufmann, Martin, additional, Eder, Matthias, additional, Bertz, Hartmut, additional, and Grishina, Olga, additional

Published
2024
Full Text
View/download PDF

15. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis

Author

Fischbach, Felix, primary, Richter, Johanna, additional, Pfeffer, Lena Kristina, additional, Fehse, Boris, additional, Berger, Susanna Carolina, additional, Reinhardt, Stefanie, additional, Kuhle, Jens, additional, Badbaran, Anita, additional, Rathje, Kristin, additional, Gagelmann, Nico, additional, Borie, Dominic, additional, Seibel, Johan, additional, Ayuk, Francis, additional, Friese, Manuel A., additional, Heesen, Christoph, additional, and Kröger, Nicolaus, additional

Published
2024
Full Text
View/download PDF

17. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Author

Gagelmann, Nico, primary, Dima, Danai, additional, Merz, Maximilian, additional, Hashmi, Hamza, additional, Ahmed, Nausheen, additional, Tovar, Natalia, additional, Oliver-Caldés, Aina, additional, Stölzel, Friedrich, additional, Rathje, Kristin, additional, Fischer, Luise, additional, Born, Patrick, additional, Schäfer, Lisa, additional, Albici, Anca-Maria, additional, Schub, Natalie, additional, Kfir-Erenfeld, Shlomit, additional, Assayag, Miri, additional, Asherie, Nathalie, additional, Wulf, Gerald Georg, additional, Kharboutli, Soraya, additional, Müller, Fabian, additional, Shune, Leyla, additional, Davis, James A., additional, Anwer, Faiz, additional, Vucinic, Vladan, additional, Platzbecker, Uwe, additional, Ayuk, Francis, additional, Kröger, Nicolaus, additional, Khouri, Jack, additional, Gurnari, Carmelo, additional, McGuirk, Joseph, additional, Stepensky, Polina, additional, Abdallah, Al-Ola, additional, and Fernández de Larrea, Carlos, additional

Published
2024
Full Text
View/download PDF

18. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis

Author

Akahoshi, Yu, primary, Spyrou, Nikolaos, additional, Hoepting, Matthias, additional, Aguayo-Hiraldo, Paibel, additional, Ayuk, Francis Ayuketang, additional, Chanswangphuwana, Chantiya, additional, Choe, Hannah K, additional, Eder, Matthias, additional, Etra, Aaron M., additional, Grupp, Stephan A., additional, Hexner, Elizabeth O., additional, Hogan, William J, additional, Kitko, Carrie L., additional, Kraus, Sabrina, additional, Al Malki, Monzr M, additional, Merli, Pietro, additional, Qayed, Muna, additional, Reshef, Ran, additional, Schechter-Finkelstein, Tal, additional, Ullrich, Evelyn, additional, Vasova, Ingrid, additional, Wölfl, Matthias, additional, Zeiser, Robert, additional, Baez, Janna, additional, Beheshti, Rahnuma, additional, Eng, Gilbert W, additional, Gleich, Sigrun, additional, Kasikis, Stelios, additional, Katsivelos, Nikolaos, additional, Kowalyk, Steven, additional, Morales, George, additional, Young, Rachel, additional, DeFilipp, Zachariah, additional, Ferrara, James L.M., additional, Levine, John E, additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

19. The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)

Author

Akahoshi, Yu, primary, Spyrou, Nikolaos, additional, Weber, Daniela, additional, Aguayo-Hiraldo, Paibel Ixia, additional, Ayuk, Francis, additional, Bunworasate, Udomsak, additional, Choe, Hannah, additional, Eder, Matthias, additional, Etra, Aaron, additional, Grupp, Stephan A., additional, Hexner, Elizabeth O, additional, Hogan, William J., additional, Kitko, Carrie L., additional, Kraus, Sabrina, additional, Merli, Pietro, additional, Qayed, Muna, additional, Reshef, Ran, additional, Schechter, Tal, additional, Ullrich, Evelyn, additional, Vasova, Ingrid, additional, Wölfl, Matthias, additional, Zeiser, Robert, additional, Baez, Janna, additional, Beheshti, Rahnuma, additional, Gleich, Sigrun, additional, Katsivelos, Nikolaos, additional, Kowalyk, Steven, additional, Morales, George, additional, Young, Ms. Rachel, additional, Chen, Dr. Yi-Bin, additional, Nakamura, Ryotaro, additional, Ferrara, James, additional, and Levine, John E, additional

Published
2024
Full Text
View/download PDF

20. The MAGIC Algorithm Probability Predicts Treatment Response and Long-Term Outcomes to Second-Line Therapy for Acute Gvhd

Author

DeFilipp, Zachariah, primary, Kim, Haesook T, additional, Spyrou, Nikolaos, additional, Kasikis, Stelios, additional, Kowalyk, Steven, additional, Eng, Gilbert, additional, Beheshti, Rahnuma, additional, Baez, Janna, additional, Ayuk, Francis, additional, Bunworasate, Udomsak, additional, Choe, Hannah, additional, Etra, Aaron, additional, Grupp, Stephan A., additional, Hexner, Elizabeth O, additional, Hogan, William J., additional, Kitko, Carrie L., additional, Qayed, Muna, additional, Reshef, Ran, additional, Vasova, Ingrid, additional, Zeiser, Robert, additional, Young, Ms. Rachel, additional, Holler, Ernst, additional, Ferrara, James, additional, Nakamura, Ryotaro, additional, Levine, John E, additional, and Chen, Dr. Yi-Bin, additional

Published
2024
Full Text
View/download PDF

22. Development and Validation of a Concise Objectifiable Risk Evaluation Score for Non-Relapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation

Author

Weise, Gunnar, primary, Massoud, Radwan, additional, Krause, Rolf, additional, Heidenreich, Silke, additional, Janson, Dietlinde, additional, Klyuchnikov, Evgeny, additional, Wolschke, Christine, additional, Zeck, Gaby, additional, Kröger, Nicolaus, additional, and Ayuk, Francis, additional

Published
2024
Full Text
View/download PDF

25. Management of Patients Undergoing CAR-T Cell Therapy in Germany.

Author

Penack, Olaf, Dreger, Peter, Ajib, Salem, Ayuk, Francis, Baermann, Ben-Niklas, Bug, Gesine, Kriege, Oliver, Jentzsch, Madlen, Kobbe, Guido, Koenecke, Christian, Lutz, Mathias, Martin, Sonja, Schlegel, Paul-Gerhard, Schroers, Roland, von Tresckow, Bastian, Vucinic, Vladan, Subklewe, Marion, Bethge, Wolfgang, and Wolff, Daniel

Subjects
STEM cell transplantation, CELLULAR therapy, HEMATOPOIETIC stem cell transplantation, CELL transplantation, CYTOKINE release syndrome, NON-Hodgkin's lymphoma
Abstract

Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin's lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. Methods: To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. Results: We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no – or low quality – clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. Conclusion: The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Allogeneic hematopoetic stem cell transplant for patients with refractory T‐Cell lymphomas.

Author

Massoud, Radwan, Naim, Hassan, Klyuchnikov, Evgeny, Janson, Dietlinde, Wolschke, Christine, Ayuk, Francis, and Kröger, Nicolaus

Subjects
STEM cell transplantation, T cells, LYMPHOMAS, GRAFT versus host disease, OVERALL survival, REFRACTORY materials
Abstract

Objective: Allogeneic stem cell transplantation (allo‐SCT) may have a curative potential due to the graft versus lymphoma effect. In this study, we aimed to compare transplant outcomes between refractory‐T‐NHL (ref‐NHL) and Chemosensitive‐T‐NHL (CS‐T‐NHL). Materials and Methods: We retrospectively reviewed the records of 26 ref‐NHL and 29 CS‐T‐NHL consecutive patients who underwent allo‐SCT at our center and compared the transplant outcomes between the groups. Results: All patients were heavily pretreated with 27% of patients relapsing post‐auto‐SCT and two patients in the ref‐T‐NHL post‐allo‐SCT. Patients were transplanted mainly from unrelated donors. There were no differences in leucocytes and platelet engraftment between the two groups. At 3 years, the relapse incidence was 34% in Ref‐TNHL and 19% in CS‐TNHL (p =.33), with non‐relapse mortality rates of 28% and 22%, respectively (p =.52). Female patients and those with a previous auto‐SCT had lower relapse incidence (p =.045, p =.003). The 3‐year overall survival was 39% in Ref‐TNHL and 56% in CS‐TNHL (p =.15). Trends for improved progression‐free survival (PFS) and graft‐versus‐host disease relapse‐free survival (GRFS) were observed in the CS‐TNHL group (PFS: 60% vs. 30%, p =.075; GRFS: 38% vs. 21%, p =.1). Conclusion: Acknowledging the retrospective nature of our study, our results indicate that allo‐SCT has a curative potential in patients with T‐NHL even in refractory status. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study

Author

Ayuk, Francis, Wagner-Drouet, Eva-Maria, Wolff, Daniel, von Huenerbein, Natascha, von Pein, Ute-Marie, Klyuchnikov, Evgeny, von Harsdorf, Stephanie, Koenecke, Christian, Sayer, Herbert, and Kröger, Nicolaus

Abstract

Although most patients with chronic graft-versus-host disease (cGVHD) show initial response to first-line therapy, long-term clinically meaningful success of first-line treatment remains rare. In a prospective multicentre phase II trial in 6 German centers, patients with newly diagnosed moderate or severe cGVHD received prednisone and everolimus for 12 months followed by a 1-year follow-up period. Primary endpoint was treatment success (TS) at 6 months defined as patient being alive, achieving PR or CR of cGVHD, having no relapse of underlying disease and requiring no secondary treatment for cGVHD. Of the 34 patients evaluable for efficacy, 19 (56%) had TS at 6 months with 22 and 52% of the patients in a CR and PR respectively. Overall 30 patients (88%) had a CR or PR as best response, nearly all responses (29/30) occurring within the first 6 weeks of treatment. The cumulative incidence of treatment failure at 1 year was 63%, corresponding to 37% TS. Predefined safety endpoint (thrombotic microangiopathy, pneumonitis, and avascular necrosis) were not observed in any patient. Addition of everolimus to prednisolone is well tolerated and may improve long-term treatment success. Larger studies are necessary to ascertain the possible role of everolimus in first-line treatment of cGVHD.

Published
2024
Full Text
View/download PDF

29. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Author

Spanjaart, Anne Mea, Ljungman, Per, de La Camara, Rafael, Tridello, Gloria, Ortiz-Maldonado, Valentín, Urbano-Ispizua, Alvaro, Barba, Pere, Kwon, Mi, Caballero, Dolores, Sesques, Pierre, Bachy, Emmanuel, Di Blasi, Roberta, Thieblemont, Catherine, Calkoen, Friso, Mutsaers, Pim, Maertens, Johan, Giannoni, Livia, Nicholson, Emma, Collin, Matthew, Vaz, Carlos Pinho, Metafuni, Elisabetta, Martinez-Lopez, Joaquin, Dignan, Fiona L., Ribera, Josep-Maria, Nagler, Arnon, Folber, Frantisek, Sanderson, Robin, Bloor, Adrian, Ciceri, Fabio, Knelange, Nina, Ayuk, Francis, Kroger, Nicolaus, Kersten, Marie José, and Mielke, Stephan

Published
2024
Full Text
View/download PDF

30. Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease.

Author

Bonig, Halvard, Verbeek, Mareike, Herhaus, Peter, Braitsch, Krischan, Beutel, Gernot, Schmid, Christoph, Müller, Nadine, Bug, Gesine, Döring, Michaela, von Stackelberg, Arend, Tischer, Johanna, Ayuk, Francis, Wulf, Gerald, Holtick, Udo, Pfeffermann, Lisa‑Marie, Jahrsdörfer, Bernd, Schrezenmeier, Hubert, Kuci, Selim, Kuci, Zyrafete, and Zens, Anke

Subjects
GRAFT versus host disease, STROMAL cells, ACUTE diseases
Published
2024
Full Text
View/download PDF

31. Hope for Motherhood: Pregnancy After Allogeneic Hematopoietic Cell Transplantation – a National Multicenter Study

Author

Sockel, Katja, Neu, Annika, Goeckenjan, Maren, Ditschkowski, Markus, Hilgendorf, Inken, Kröger, Nicolaus, Ayuk, Francis A., Stoelzel, Friedrich, Middeke, Jan Moritz, Eder, Matthias, Bethge, Wolfgang, Finke, Jürgen, Bertz, Hartmut, Kobbe, Guido, Kaufmann, Martin, Platzbecker, Uwe, Beverungen, David, Schmid, Christoph, von Bonin, Malte, Egger-Heidrich, Katharina, Heberling, Lisa, Trautmann-Grill, Karolin, Teipel, Raphael, Bug, Gesine, Tischer, Johanna, Fraccaroli, Alessia, Fante, Matthias, Wolff, Daniel, Luft, Thomas, Winkler, Julia, Schäfer-Eckart, Kerstin, Scheid, Christof, Holtick, Udo, Klein, Stefan, Blau, Igor Wolfgang, Burchert, Andreas, Wulf, Gerald, Hasenkamp, Justin, Schwerdtfeger, Rainer, Kaun, Stephan, Junghanss, Christian, Wortmann, Friederike, Winter, Susann, Neidlinger, Helga, Theuser, Catrin, Beyersmann, Jan, Bornhaeuser, Martin, Schmeller, Sandra, Schetelig, Johannes, Jost, Edgar, Schmid, Christoph, Baurmann, Herrad, Blau, Igor, Holderried, Tobias, Hertenstein, Bernd, Hänel, Mathias, Bornhäuser, Martin, Neidlinger, Helga, Kobbe, Guido, Winkler, Julia, Schroeder, Thomas, Bug, Gesine, Hopfer, Olaf, Finke, Jürgen, Hasenkamp, Justin, Krüger, William, Müller, Lutz, Kröger, Nikolaus, Eder, Matthias, Luft, Thomas, Hilgendorf, Inken, Ringhoffer, Mark, Stölzel, Friedrich, Scheid, Christoph, Platzbecker, Uwe, Wortmann, Friederike, Heinicke, Thomas, Wagner, Eva, Klein, Stefan, Burchert, Andreas, Tischer, Johanna, Stelljes, Matthias, Schäfer-Eckart, Kerstin, Wolff, Daniel, Junghanss, Christian, Ritter, Markus, Kaufmann, Martin, Bethge, Wolfgang, Mytilineos, Joannis, and Einsel, Hermann

Abstract

•Successful pregnancies are possible among female alloHCT recipients, although birth rate is more than six times lower than in the general population.•Key factors increasing the chance of motherhood were younger age at HCT, non-malignant disease, no TBI or dose <8Gy and RIC/NMA conditioning

Published
2024
Full Text
View/download PDF

32. Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation.

Author

Steiner N, Massoud R, Klyuchnikov E, Gagelmann N, Richter J, Niederwieser C, Rathje K, Urbanowicz T, Kunte A, Engelmann J, Ihne C, Lastovytska I, Lindhauer C, Marquard F, Reichard M, Ryzhkova A, Sabauri R, Schäfersküpper M, Seyedi N, Kalogeropoulos G, Heidenreich S, Rudolph I, Zeck G, Janson D, Wolschke C, Ayuk F, and Kröger N

Abstract

We retrospectively analyzed high-risk ALL patients in CR1 receiving total body irradiation based conditioning regimen with ATLG (n = 74) or PTCy (n = 73) for GVHD prophylaxis. The 3-year OS and LFS were similar in both groups: 65 and 60% in the ATLG group and 64 and 67% in the PTCy group (p = 0.9 and 0.5, respectively). CIR and NRM rate at three years was 12 and 21% after PTCy and 19 and 20% after ATLG (p = 0.4 and p = 0.9, respectively). Acute GvHD grades II-IV and grades III/IV at 100 days was 46 and 19% after PTCy and 33 and 10% after ATLG (p = 0.08 and p = 0.9, respectively). Chronic GvHD of all grade at two years was higher after PTCy: 55% versus 26% (p < 0.001). Based on the propensity score matching (PSM) analysis, aGvHD grades II-IV was trending higher in the PTCy group compared to the ATLG group (p = 0.07). In contrast to the PSM analysis, on multivariate analysis the receipt of PTCy compared with ATLG was associated with a reduced CIR (p = 0.026). Our retrospective single-center analysis shows a lower incidence of acute and chronic GvHD while displaying similar LFS and OS after ATLG compared to PTCy in TBI based allogeneic stem cell transplantation for high-risk ALL., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

33. Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study.

Author

Kröger N, Wulf G, Hegenbart U, Burchert A, Stelljes M, Gagelmann N, Brecht A, Kaufmann M, Müller L, Ganser A, Wolf D, Bethge W, Bornhäuser M, Kiehl M, Wagner EM, Schmid C, Reinhardt HC, Kobbe G, Salwender H, Heinicke T, Kropff M, Heinzelmann M, Ayuk F, Trümper L, Neubauer A, Völp A, Kluychnikov E, Schönland S, and Wolschke C

Subjects
Humans, Middle Aged, Male, Female, Adult, Prospective Studies, Transplantation, Homologous, Treatment Outcome, Multiple Myeloma therapy, Multiple Myeloma mortality, Multiple Myeloma diagnosis, Thalidomide administration & dosage, Thalidomide therapeutic use, Hematopoietic Stem Cell Transplantation methods, Transplantation, Autologous, Maintenance Chemotherapy
Abstract

The role of autologous-allogeneic tandem stem cell transplantation (alloTSCT) followed by maintenance as upfront treatment for multiple myeloma is controversial. Between 2008 and 2014 a total of 217 multiple myeloma patients with a median age of 51 years were included by 20 German centers within an open-label, parallel-group, multicenter clinical trial to compare alloTSCT to autologous tandem transplantation (autoTSCT) followed by 2 years of maintenance therapy with thalidomide (100 mg/day) in both arms with respect to relapse/progression-free survival (PFS) and other relevant outcomes. A total of 178 patients underwent a second transplant (132 allogeneic, 46 autologous). PFS at 4 years after the second transplant was 47% (95% CI: 38-55%) for alloTSCT and 35% (95% CI: 21-49%) for autoTSCT (P=0.26). This difference increased to 22% at 8 years (P=0.10). The cumulative incidences of non-relapse mortality and of relapse at 4 years were 13% (95% CI: 8-20%) and 2% (95% CI: 0.3-2%) (P=0.044) and 40% (95% CI: 33-50%) and 63% (95% CI: 50-79%) (P=0.04) for alloTSCT and autoTSCT, respectively. The difference for relapse/progression increased to 33% (alloTSCT: 44%, autoTSCT: 77%) at a median follow-up of 82 months (P=0.002). Four-year overall survival was 66% (95% CI: 57-73%) for alloTSCT and 66% (95% CI: 50-78%) for autoTSCT (P=0.91) and 8-year overall survival was 52% and 50% (P=0.87), respectively. In conclusion, alloTSCT followed by thalidomide maintenance reduced the rate of recurrence or progression during a follow-up period of up to 10 years but failed to improve PFS significantly. This study was registered with ClinicalTrials.gov (NCT00777998).

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results